Market Size, Share, Trends and Forecast, 2028

Thrombosis Drug Market: Industry Perspective

The global thrombosis drug market is likely to grow from $25,892 million in 2021 to $47,789 million by the end of 2028. It is likely to exhibit exponential growth with a healthy CAGR of 9.51% during the forecast period. The report presents comprehensive projections on the growth factors, opportunities, and restraining factors.

Request Free Sample

Thrombosis Drug Market: Overview

Thrombosis drugs are referred to as the ones that inhibit the working of platelets, avoid clot formation, and further inhibit the formation of other new clots. These drugs help prevent myriad conditions like deep vein thrombosis and atrial fibrillation. Such drugs have many side effects like bleeding gums & noses, heavy menstrual periods, vomiting, and bleeding. Thrombosis treatment is used to cure the clots to avoid the blockage of an organ. The drugs adopted in the treatment of thrombosis are also referred to as blood thinners.

Thrombosis is a condition in which blood gets a clot in the blood vessel, which leads to the obstruction of blood flow in the circulatory system and it may travel to the other body parts. Thrombosis drugs are those drugs which are used to treat the blood clots formed in the blood arteries and veins. These drugs generally include anticoagulant drugs and thrombin inhibitor drugs which dilute the blood and dissolve the blood clot in the arteries and veins and also reduce the chances of embolism. These drugs are available in the form of a capsule, tablet, and injection. As per the Center for Disease Control and Prevention report 2015, the exact number of people diagnosed with deep vein thrombosis or pulmonary embolism is not known, although it is estimated that 900,000 people could be affected (1 to 2 per 1,000) each year in the United States.

COVID-19 Impact:

The Covid-19 outbreak has led to a negative impact on the global thrombosis drug market because the primary concentration of government, healthcare centers, and pharmaceutical companies was to prioritize the treatment of coronavirus. They all took the initiative to prevent the spread of Covid-19 cases further. Therefore, they were engaged in the development of vaccines and drugs along with the focus on optimizing the medicine supply chain logistics. The whole healthcare sector prioritized the Covid treatment, and therefore other treatments were given secondary importance. Additionally, the research and development pipeline also concentrated on innovating anti-covid solutions. However, the surge in demand for drugs from the pharmaceutical and biotechnology sector is likely to throw strong growth prospects in the global market in the forthcoming years.

Request Free Sample

Thrombosis Drug Market: Growth Drivers

Increasing consumption of tobacco and liquor will drive the growth of the global market.

As per the report from the World Health Organization, it is found that one in three people is overweight. Such statistics are due to the increasing consumption of tobacco and liquor, which is likely to scale up the risk of obesity. Such a landscape further creates critical hypertension, which causes thrombosis-associated problems. Therefore, it is likely to fuel the growth of the global thrombosis drug market exponentially in the forthcoming years. Another crucial factor fueling the growth of the global market is the growing awareness among people regarding the importance of cardiovascular health. However, treating cardiovascular problems with medication is a multifaceted approach, but people are also adopting blood thinner medication as a critical treatment for their problems. Additionally, a number of manufacturers introduced many anticoagulants which address the issues associated with the prevention of blood clots. Such a market landscape will expand the scope of thrombosis drugs. Simultaneously, there is a spike in the number of cases associated with myocardial problems and coronary heart disease, which is also likely to contribute to the growth of the market.

The major factors driving the growth of thrombosis drug market are increased the prevalence of thrombosis coupled with the availability of new products. As per the International Society on Thrombosis and Haemostasis report every year, there are approximately 10 million cases of venous thromboembolism recorded worldwide. There are various companies which are constantly working for the development of various new and effective drugs which is expected to provide better results as compared to conventional drugs. The companies have research and development department which helps in the development of these drugs and further launch of new drugs in the area of treatment are further expected to promote the growth of thrombosis treatment market. Moreover, unmet needs of people and significant technological advancements in the healthcare sectors and new product launches are expected to fuel the growth of thrombosis drug market. However, increased use of generic drugs is expected to hamper the growth of thrombosis drug market over the forecast period.

Thrombosis Drug Market: Restraints

Lack of awareness among patients is likely to spur the growth of the global market.

Thrombosis is a result of certain cardiovascular problems due to aging, and nowadays, the geriatric population is growing rapidly. But simultaneously, there is a lack of awareness among people regarding the seriousness of thrombosis, which in turn will also hamper the growth of the global market.

Thrombosis Drug Market: Opportunities

Increasing geriatric population is likely to open new avenues in the global market.

Thrombosis is common in the aging population because it is caused due to cardiovascular problems, which are highly found in aged people. Additionally, the growing disposable income of people is further encouraging them to adopt complete and successful treatment, which is likely to expand the scope of the global market.

Thrombosis Drug Market: Challenges

Side effects of thrombosis drugs are a huge challenge in the global market.

For instance, the common side effect of such drugs is uncontrolled bleeding. Furthermore, anti-clotting medications often cause a stroke. Therefore, such conditions are likely to be a huge challenge in the global market.

Thrombosis Drug Market: Segmentation

The global thrombosis drug market can be segmented into disease type, distribution channel, drug class, and region.

By disease type, the market can be segmented into atrial fibrillation, pulmonary embolism, and deep vein thrombosis.

By distribution channel, the market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

By drug class, the market can be segmented into heparin, Xa inhibitor, and P2Y12 platelet inhibitor.

Report Scope:

Recent Developments

• Mylan N.V. revealed that it had signed an agreement to take over Aspen Pharmacare Holdings Ltd. in Europe in September 2020.
• The Story Brook found that using anticoagulation solution lowers the mortality in severe cases of Covid-19 patients in February 2021.

Thrombosis Drug Market: Regional Landscape

North America to hold the largest market share.

North America swipes the largest share in the global thrombosis drug market due to the presence of well-established health infrastructure in the region. Additionally, the presence of proper reimbursement medical policies is further encouraging people to opt for complete thrombosis treatment. Furthermore, the presence of prominent market leaders will also expand the scope of the regional market.

Thrombosis Drug Market: Competitive Landscape

Some of the significant players in the global thrombosis drug market include :

• Pfizer
• Aspen Pharmacare Holdings Limited
• Bayer AG
• AstraZeneca plc
• Sanofi
• Johnson & Johnson
• Bristol-Myers Squibb Company
• Baxter International Inc.
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc.

Global thrombosis drug market is segmented as follows:

By Disease type

• Deep vein thrombosis
• Pulmonary embolism
• Atrial fibrillation

By Distribution channel

• Online pharmacies
• Hospital pharmacies
• Retail pharmacies

By Drug class

• P2Y12 platelet inhibitor
• Xa inhibitor
• Heparin

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa